First Hawaiian Bank Veracyte, Inc. Transaction History

First Hawaiian Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 08, 2024	SELL	$19.72 - $28.68 $47,919 - $69,692	-2,430 Reduced 14.57%	14,250 $392,000
Q3 2023 Oct 10, 2023	SELL	$22.33 - $29.92 $6,475 - $8,676	-290 Reduced 1.71%	16,680 $372,000
Q2 2023 Jul 06, 2023	BUY	$20.96 - $26.99 $125,550 - $161,670	5,990 Added 54.55%	16,970 $432,000
Q4 2020 Jan 12, 2021	SELL	$32.49 - $61.88 $155,952 - $297,024	-4,800 Reduced 30.42%	10,980 $537,000
Q3 2020 Oct 06, 2020	SELL	$26.73 - $35.67 $67,626 - $90,245	-2,530 Reduced 13.82%	15,780 $513,000
Q1 2020 Apr 21, 2020	SELL	$16.13 - $30.17 $7,984 - $14,934	-495 Reduced 2.63%	18,310 $445,000
Q3 2019 Oct 03, 2019	SELL	$23.87 - $30.93 $124,362 - $161,145	-5,210 Reduced 21.69%	18,805 $451,000
Q2 2019 Jul 15, 2019	SELL	$22.1 - $28.56 $47,846 - $61,832	-2,165 Reduced 8.27%	24,015 $685,000
Q1 2019 Apr 02, 2019	SELL	$12.0 - $25.76 $56,880 - $122,102	-4,740 Reduced 15.33%	26,180 $655,000
Q3 2018 Oct 16, 2018	BUY	$9.55 - $12.64 $295,286 - $390,828	30,920 New	30,920 $295,000

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

Stay updated on First Hawaiian Bank with notifications on news.